Have a personal or library account? Click to login
The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer Cover

The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer

Forum of Clinical Oncology
Volume 10 (2019): Issue 2 (December 2019)
By: Tzelepi C. Vasiliki,  Gogadis T. Aristeidis,  Adamidis K. Christos and  Eleni T. Timotheadou  
Open Access
|Apr 2020
DOI: https://doi.org/10.2478/fco-2019-0007 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 2 - 14
Submitted on: May 12, 2019
Accepted on: Oct 7, 2019
Published on: Apr 5, 2020
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Breast cancer,
CDK4/6 inhibitors,
toxicity,
drug interactions,
clinical management
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2020 Tzelepi C. Vasiliki, Gogadis T. Aristeidis, Adamidis K. Christos, Eleni T. Timotheadou, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 10 (2019): Issue 2 (December 2019)Next article